上海美农生物科技股份有限公司 证券代码：301156 证券简称：美农生物 公告编号：2023-040 关于召开 2023 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）和《公司章程》 的规定，经上海美农生物科技股份有限公司（以下简称"公司"或"本公司"） 第五届董事会第二次会议审议通过，公司决定于 2023 年 9 月 14 日（星期四）召 开公司 2023 年第一次临时股东大会。现将会议相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2023 年第一次临时股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召开符合《公司法》《深圳 证券交易所创业板股票上市规则》等有关法律、法规、部门规章、规范性文件及 《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议召开的时间：2023 年 9 月 14 日（星期四）下午 2:30； （2）网络投票时间：2023 年 9 月 14 日（星期四）； 其中，通过深圳证券交易所（以下简称 ...

证券代码：301156 证券简称：美农生物 | --- | --- | --- | --- | |----------------|----------------------------------------|----------------------------------------|---------------| | | | | 编号：2023-06 | | | 特定对象调研 □分析师会议 | | | | 投资者关系 | □媒体采访 □业绩说明会 | | | | 活动类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □其他（请文字说明其他活动内容） | | | | | 国弘天下资本集团有限公司 | 孙世文等 | | | 参与单位名称及 | 上海泽恒基金管理有限公司 | 张鹏 | | | 人员姓名 | 上海万得基金销售有限公司 | 唐晗哲 | | | | 首创证券股份有限公司 | 顾寅等 | | | 时间 | 2023 年 7 月 13 日（周四） | 10:00-12:00 | | | 地点 | 公司会议室 | | | | | 董事会秘书：张维娓 | | | ...

证券代码：301156 证券简称：美农生物 上海美农生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------------|------------------------| | | | 编号：2023-05 | | | 特定对象调研 □分析师会议 | | | 投资者关系 | □媒体采访 □业绩说明会 | | | 活动类别 | □新闻发布会 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称及 | 国新证券股份有限公司 | | | 人员姓名 | 深圳宽裕资产管理有限公司 | | | 时间 | 2023 年 6 月 28 日（周三） | | | 地点 | 公司办公室 | | | 上市公司接待 | 董事会秘书：张维娓 | | | 人员姓名 | 证券事务代表：彭巧 | | | | | | | | | | | | 1、相比 2022 | 年业绩下滑的主要原因及 | | | 应对措施有哪些？ | | | | | | | | | | | 投资者关系活动 | ...

证券代码：301156 证券简称：美农生物 上海美农生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------------|--------| | | | 编号： | | | 特定对象调研 □分析师会议 | | | 投资者关系 | □媒体采访 □业绩说明会 | | | 活动类别 | □新闻发布会 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | | 首创证券股份有限公司 | | | 参与单位名称及 | 首创京都期货有限公司 | | | 人员姓名 | 东方财富证券股份有限公司 | | | | 上海睿华资产管理有限公司 | | | 时间 | 2023 年 6 月 14 日（周三） | | | 地点 | 公司办公室 | | | | 董事会秘书：张维娓 | | | 上市公司接待 | | | | | 财务总监：周茜 | | | 人员姓名 | | | | | 市场部总监：张吉海 | | 本次活动采用现场交流的方式举行，主要交流内容如下： 1、与同类公司相比，公司的核心 ...

证券代码：301156 证券简称：美农生物 上海美农生物科技股份有限公司 投资者关系活动记录表 | --- | --- | |----------------|------------------------------------| | | | | 投资者关系 | □媒体采访 | | 活动类别 | □新闻发布会 | | | □现场参观 | | | 其他（2023 | | 参与单位名称及 | 线上参与"2023 | | 人员姓名 | 的投资者 | | 时间 | 2023 年 5 月 10 | | 地点 | "上证路演中心"（ | | | 董事长兼总经理：洪伟 | | 上市公司接待 | | | | 董事、副总经理、董事会秘书：张维娓 | | 人员姓名 | | | | 财务总监：周茜 | | | 公司于 2023 年 5 月 | | | 心"（ | | | | | | | 投资者关系活动 1、问：请问公司今年是否有信心完成较好的业绩，来回馈公 主要内容介绍 司的投资者？公司今年的增长点主要是哪些？ 答：尊敬的投资者，您好，公司管理层对公司的长期经营和发 展充满信心。公司将继续聚焦猪、反刍、家禽、水产、宠物等 领域 ...

证券代码：301156 证券简称：美农生物 上海美农生物科技股份有限公司 投资者关系活动记录表 | --- | --- | |----------------|------------------------------------| | | | | 投资者关系 | □媒体采访 | | 活动类别 | □新闻发布会 | | | □现场参观 | | | 其他（请文字说明其他活动内容） | | 参与单位名称及 | | | | 线上参与"2022 | | 人员姓名 | | | 时间 | 2023 年 5 月 9 | | 地点 | 全景网"投资者关系互动平台"（ | | | 董事长兼总经理：洪伟 | | | 董事、副总经理、董事会秘书：张维娓 | | 上市公司接待 | | | | 财务总监：周茜 | | 人员姓名 | | | | 独立董事：向川 | | | 保荐代表：吴彦栋 | | | 公司于 2023 年 5 月 | | | 台"（https://ir.p5w.net | | | | | | 如下： | | 投资者关系活动 | | | 主要内容介绍 | | | | | | | | | | | 2、问：公司业绩尚可，分 ...

Financial Performance - The company's operating revenue for 2022 was ¥483,316,843.54, a decrease of 11.52% compared to ¥546,254,749.11 in 2021[21] - The net profit attributable to shareholders for 2022 was ¥52,491,989.65, down 25.60% from ¥70,557,737.30 in the previous year[21] - The net cash flow from operating activities decreased by 53.29% to ¥42,054,260.09 in 2022, compared to ¥90,039,563.92 in 2021[21] - Basic earnings per share for 2022 were ¥0.75, a decline of 36.44% from ¥1.18 in 2021[21] - The net profit after deducting non-recurring gains and losses for 2022 was ¥50,093,706.88, a decrease of 22.05% from ¥64,260,852.79 in 2021[21] - The weighted average return on net assets decreased to 9.49% in 2022 from 24.42% in 2021, a drop of 14.93%[21] - The company's total assets at the end of 2022 were ¥887,046,604.86, an increase of 67.46% compared to the previous year, while net assets attributable to shareholders grew by 141.14% to ¥781,659,719.39[72] - The sales of functional feed additives accounted for 59.32% of total revenue, with a year-on-year decline of 18.17%[80] - The sales of nutritional feed additives increased by 7.21% year-on-year, reaching ¥91,472,033.06, representing 18.93% of total revenue[80] - The company's overseas revenue accounted for 25.01% of total revenue, with a slight increase of 0.27% year-on-year[80] Market and Industry Trends - The total production of industrial feed in China reached 30.22 million tons in 2022, representing a year-over-year growth of 3.0%[32] - The market for feed additives in China saw a product value increase of 9.8% in 2022, totaling CNY 126.77 billion[33] - The overall livestock production in China was stable, with a total meat output of 92.27 million tons in 2022, marking a growth of 3.8% compared to the previous year[31] - The demand for animal protein is increasing due to rising living standards, leading to a growing need for feed additives that enhance livestock production efficiency and ensure food safety[35] - The transition from traditional to modern, resource-efficient, and environmentally friendly livestock farming requires "green, safe, and efficient" feed additives[36] - The feed industry is experiencing stable growth, driven by high demand for animal products, despite short-term fluctuations due to livestock inventory changes[40] - The trend towards large-scale farming is increasing the demand for feed additives, as larger operations focus on improving overall production efficiency[43] Research and Development - The company has a strong focus on R&D, with significant investments leading to breakthroughs in core technologies and product formulation[48] - The company’s functional feed additives include flavoring agents and acidity regulators, aimed at improving feed quality and promoting animal growth[54] - The company is focused on the research and development of functional protein products and efficient protein nutrition strategies to support the sustainable development of the livestock industry[131] - Ongoing research and development efforts have led to the introduction of two new technologies aimed at improving product efficiency, projected to reduce costs by 15%[171] Risk Management and Compliance - The company has outlined potential risks and countermeasures in its future development outlook section[3] - The company has implemented risk control measures for foreign exchange transactions, focusing on hedging to mitigate currency fluctuation risks[111] - The company has established clear regulations and procedures for risk management and internal audits related to foreign exchange transactions[111] - The company has maintained compliance with regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[184] Corporate Governance - The company held 4 board meetings during the reporting period, adhering strictly to legal and regulatory requirements[143] - The supervisory board also convened 4 times, ensuring compliance with laws and regulations while safeguarding the rights of shareholders[144] - The company maintains a high level of information disclosure, ensuring that all shareholders have equal access to information through designated media[145] - The company has established independent financial, personnel, and operational structures, ensuring no asset occupation by controlling shareholders[148][149][150][151][152][153] Employee and Talent Development - By the end of 2022, the company had 62 employees with master's degrees and 95 with bachelor's degrees, indicating a growing and professional talent pool[71] - The company has established a complete training system to enhance talent development and improve employee skills[190] - The total number of employees at the end of the reporting period was 390, with 219 in the parent company and 171 in major subsidiaries[188] Future Outlook and Strategic Initiatives - The company plans to enhance its product offerings and market competitiveness through ongoing R&D efforts and new product launches in the feed additives sector[91] - The company aims to strengthen its feed additive business, focusing on pig products while expanding into ruminant, poultry, aquaculture, and pet products[129] - The company intends to enhance its market share in pig products and expand its offerings in acid regulators and gut health products[129] - The company plans to adjust the completion date of its new feed-related product production project to April 30, 2024, due to delays caused by economic downturns and logistical challenges[119] Financial Management and Capital Structure - The company raised a total of 469.6 million RMB from its initial public offering, with a net amount of 405.0331 million RMB after deducting issuance costs[116] - The company has a dedicated account for raised funds, which will be used for subsequent payments related to investment projects[116] - The company has reported a total of 296.7 thousand RMB in interest income and investment returns from the raised funds account[116] - The total distributable profit for shareholders as of December 31, 2022, was RMB 239,672,058.14, with a cumulative undistributed profit of RMB 191,080,060.29[196] Awards and Recognition - The company has received multiple honors, including being named one of the "Top Ten Outstanding Achievements in the Chinese Aquaculture Industry" in 2022[50] - The company has received multiple awards, including recognition as one of the "Top 30 Innovative Feed Enterprises" in China, enhancing its brand reputation[70]

Financial Performance - The company's revenue for Q1 2023 was ¥91,015,564.31, a decrease of 14.24% compared to ¥106,122,346.48 in the same period last year[5] - Net profit attributable to shareholders was ¥9,539,039.25, down 35.38% from ¥14,760,900.08 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 91,015,564.31, a decrease of 14.2% compared to CNY 106,122,346.48 in Q1 2022[21] - Net profit for Q1 2023 was CNY 9,539,039.25, representing a decline of 35.5% from CNY 14,760,900.08 in Q1 2022[22] - Earnings per share for Q1 2023 was CNY 0.12, down from CNY 0.25 in Q1 2022[22] Cash Flow and Liquidity - The net cash flow from operating activities improved by 43.97%, reaching -¥11,127,387.13 compared to -¥19,858,081.72 in the previous year[5] - The cash inflow from operating activities for Q1 2023 was CNY 136,716,036.51, an increase of 37.2% compared to CNY 99,605,205.03 in Q1 2022[24] - The total cash and cash equivalents at the end of Q1 2023 stood at CNY 351,162,151.12, compared to CNY 75,681,974.06 at the end of Q1 2022, reflecting a significant increase[25] - Cash and cash equivalents at the end of the period increased by 364.00% to ¥351,162,151.12, primarily due to the inflow of raised funds[13] - The company received CNY 145,000,000.00 from investment recoveries, a substantial rise from CNY 30,194,780.00 in the previous year[24] Assets and Liabilities - Total assets decreased by 6.95% to ¥825,435,046.15 from ¥887,046,604.86 at the end of the previous year[5] - Total current assets decreased from 616,148,533.06 CNY to 552,265,701.21 CNY[18] - The total liabilities as of the end of Q1 2023 were CNY 34,236,287.51, a significant decrease from CNY 105,386,885.47 at the end of the previous year[22] - Total current liabilities decreased from 103,391,569.38 CNY to 32,256,785.02 CNY[18] Investments and Income - Investment income surged by 2080.98% to ¥810,948.41, mainly due to profits from joint ventures[11] - The company reported an investment income of CNY 810,948.41 in Q1 2023, compared to a loss of CNY 40,936.69 in the previous year[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,144[14] - The largest shareholder, Hong Wei, holds 38.14% of the shares, totaling 30,509,490 shares[14] Expenses - The company experienced a 55.20% increase in sales expenses, totaling ¥7,353,346.58, attributed to enhanced marketing efforts[11] - Total operating costs for Q1 2023 were CNY 82,991,701.42, down 6.5% from CNY 88,840,835.37 in the same period last year[21] - Research and development expenses increased to CNY 3,646,778.89, up from CNY 3,352,232.33 in Q1 2022, indicating a focus on innovation[21] Market Strategy - The company has not reported any new product developments or market expansion strategies in the current quarter[15] - The company aims to enhance market expansion and product development strategies in the upcoming quarters[20]

证券代码：301156 证券简称：美农生物 公告编号：20 23-023 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 8 日 15:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题 征集专题页面。敬请广大投资者通过全景网系统提交您所关注的问题，便于公司 在业绩说明会上对投资者普遍关注的问题进行回答，提升此次业绩说明会的针对 性。此次活动交流期间，投资者仍可登陆活动界面进行互动提问。 欢迎广大投资者积极参与本次网上说明会。 (问题征集专题页面二维码) 上海美农生物科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海美农生物科技股份有限公司(以下简称"公司")定于 2023 年 5月 9 日(星 期二)下午 15:00 至 17:00 在全景网举办 2022 年度业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与广大投资者的沟通交流，上海美农生物科技股份有限公司 （以下简称"公司"）将参加"2023 年上海辖区上市公司年报集体业绩说明会" 活动，现将有关事项公告如下： 本次业绩说明会活动将采取网络的方式举行，投资者可以登录"上证路演中 心"网站（http://roadshow.sseinfo.com）或关注微信公众号上证路演中心参 与活动，活动时间为 2023 年 5 月 10 日（周三）15:00 至 17:00。 证券代码：301156 证券简称：美农生物 公告编号：20 23-024 上海美农生物科技股份有限公司 关于参加 2023 年上海辖区上市公司年报集体业绩说明会的公告 届时公司的董事长洪伟先生、财务总监周茜女士、董事会秘书张维娓女士将 通过网络在线交流形式与投资者就公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关注的问题进行沟通。投资者可以通过公司邮箱 mnsw@sinomenon.com 或电话 021-59546881 进行提问，公司将在说明会上对投资 者普遍关注的 ...